<DOC>
	<DOC>NCT00718276</DOC>
	<brief_summary>We compare the effect of HyD (25-hydroxyvitamin D) and vitamin D3 in their effect on 25-hydroxyvitamin D plasma levels over a course of 4 month. This is a pharmacokinetic study including 35 postmenopausal women. - Trial with medicinal product</brief_summary>
	<brief_title>Pharmacokinetic Study: Effect of 25(OH)D and Vitamin D3 on Serum 25(OH)D</brief_title>
	<detailed_description>We include postmenopausal women age 50 to 75, race/ethnicity: Caucasian, serum 25(OH)D at baseline between 20 to 60 nmol/l, body mass index: &lt; 30 kg/m2 to compare 25(OH)D and vitamin D3 in equimolar doses over a 4 month pharmacokinetic trial. The dosing arms are daily, weekly, and bolus</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Inclusion criteria: Postmenopausal women Age 50 to 75 years Body mass index 1829 kg/m2 25hydroxyvitamin D levels 20 to 60 nmol/l Caucasian Generally healthy Exclusion criteria: Serum calcium &gt; 2.6 nmol/L Use if dietary supplements (&gt; 400 IU vitamin D per day, &gt; 600 mg of calcium per day) Hypertension Diseases that carry the risk of hypercalcemia Use of any drug that interferes with bone metabolism in the last 12 months (bisphosphonates estrogen receptor modulators, PTH, calcitonin) Oral HRT in the last 6 months Extreme diets Fracture or fall in the last 3 months Current smoking or alcohol abuse Planning on a sunny vacation in the course of the trial Kidney stone history Creatinine clearance &lt; 30 ml/min Comedications: anticoagulants, PTH, corticosteroids, thiazide diuretics, digoxin, anticonvulsants, malabsorption,z C</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Healthy postmenopausal women</keyword>
</DOC>